The stock has a 36-month beta value of 1.40. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 87.33M, and at present, short sellers hold a 14.18% of that float. On April 10, 2025, the average trading volume of DYN was 2.35M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has plunge by 10.87relation to previous closing price of 6.81. Nevertheless, the company has seen a -23.81% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-20 that WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J.
DYN’s Market Performance
Dyne Therapeutics Inc (DYN) has seen a -23.81% fall in stock performance for the week, with a -37.24% decline in the past month and a -68.34% plunge in the past quarter. The volatility ratio for the week is 16.26%, and the volatility levels for the past 30 days are at 9.40% for DYN. The simple moving average for the past 20 days is -29.11% for DYN’s stock, with a -72.70% simple moving average for the past 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with BMO Capital Markets repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see DYN reach a price target of $50. The rating they have provided for DYN stocks is “Sector Outperform” according to the report published on March 07th, 2025.
Robert W. Baird gave a rating of “Outperform” to DYN, setting the target price at $46 in the report published on December 13th of the previous year.
DYN Trading at -39.26% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.09% of loss for the given period.
Volatility was left at 9.40%, however, over the last 30 days, the volatility rate increased by 16.26%, as shares sank -38.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.91% lower at present.
During the last 5 trading sessions, DYN fell by -23.81%, which changed the moving average for the period of 200-days by -78.44% in comparison to the 20-day moving average, which settled at $10.65. In addition, Dyne Therapeutics Inc saw -67.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Friedl-Naderer Johanna, who sale 143 shares at the price of $12.12 back on Mar 13 ’25. After this action, Friedl-Naderer Johanna now owns 96,057 shares of Dyne Therapeutics Inc, valued at $1,733 using the latest closing price.
Scalzo Richard William, the SVP, Head of Finance & Admin. of Dyne Therapeutics Inc, sale 1,343 shares at $11.38 during a trade that took place back on Mar 11 ’25, which means that Scalzo Richard William is holding 122,330 shares at $15,283 based on the most recent closing price.
Stock Fundamentals for DYN
The total capital return value is set at -0.53. Equity return is now at value -88.03, with -74.14 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -12.19.
Currently, EBITDA for the company is -343.89 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.60.
Conclusion
To sum up, Dyne Therapeutics Inc (DYN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
